Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Change in Account Payables (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Change in Account Payables for 9 consecutive years, with -$3.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables fell 365.01% to -$3.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.5 million, a 623.31% decrease, with the full-year FY2025 number at -$7.5 million, down 623.31% from a year prior.
  • Change in Account Payables was -$3.4 million for Q4 2025 at Denali Therapeutics, up from -$4.1 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $4.8 million in Q2 2023 to a low of -$4.4 million in Q3 2024.
  • A 5-year average of $116350.0 and a median of $708500.0 in 2021 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: soared 626.11% in 2021, then crashed 2098.72% in 2022.
  • Denali Therapeutics' Change in Account Payables stood at -$78000.0 in 2021, then plummeted by 2098.72% to -$1.7 million in 2022, then decreased by 21.34% to -$2.1 million in 2023, then skyrocketed by 161.8% to $1.3 million in 2024, then tumbled by 365.01% to -$3.4 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Change in Account Payables are -$3.4 million (Q4 2025), -$4.1 million (Q3 2025), and $2.6 million (Q2 2025).